Posted by Michael Wonder on 21 Nov 2024
ImmuneSensor Therapeutics receives orphan drug and rare paediatric disease designations from the US FDA for cGAS inhibitor drug candidate, IMSB301, for the treatment of Aicardi Goutières syndrome
20 November 2024 - ImmuneSensor Therapeutics announced that the US FDA has granted both orphan drug designation and rare paediatric disease designation for the company’s lead anti-inflammatory and autoimmunity drug candidate, IMSB301 for the treatment of cGAS driven type I interferonopathy, Aicardi Goutières Syndrome.
IMSB301, a novel, orally available small molecule cGAS inhibitor is also being developed for the treatment of inflammatory and autoimmune diseases, including systemic lupus erythematosus and cutaneous lupus erythematosus.
